

APPENDIX

ANNEX I: Ethical documents and consent form

Ethical Consideration

Before we start our interview, I want to thank you for giving time to meet me today. My name is..... and I would like to brief you about the ongoing National Tuberculosis program for TB control, particularly on some of the challenges that we are routinely faced which ultimately results in low coverage as well as makes difficulties in detection of MDR-TB. So, how we can formulate an effective implementation in NTP to eliminate TB from Bangladesh, as a researcher, I am going to support the implementation program to find out the gaps and barriers. To fulfil this study purpose I am going to ask some questions regarding present situation of MDR-TB, existing NTP implementation, challenges, current practice, knowledge and health care seeking attitude, what will be some of strengths and opportunities in the current policies that you think, will very much appreciable for improving the entire NTP implementation in Bangladesh.

The interview will take less than an hour. Just to note that all your comments will be well addressed, I will record all your comments. Even though I will also take some notes during the session and please speak up a bit loud so that the tape can record our entire interview. Please remind that all responses will not be kept disclosed and will use only for the academic research purpose. This means, your interview will only be shared with research team members, though any information we include in our report does not identify you as the respondent. Please take note that you don't have to talk about anything that you don't want to disclose and even you may withdraw yourself from the interview at any time. However, there is no potential risk or financial benefit for participating in this study. So, no monetary compensation will be provided against any kind of harm.



UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community

Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc, PhD and Prof. Dr. Ari Probandari, MPH, Ph.D

Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

The study has been reviewed and approved by the ethical committee of Faculty of
Medicine, Public Health and Nursing, University of Gadjah Mada,

Indonesia (Telp: 0274 588688 pswt 17225 , +62811-2666-869, e-mail: mhrec_fmugm@ugm.ac.id). Permission also has been taken from local administrative office. If you have any question about this study, you can contact directly to **Mahfuza Talukder Flowra** (contact no: **+8801712581426** and email: flowramahfuza@gmail.com), who is the principal investigator of the study.

- Is there any question about what I have just explained?
- Are you willing to participate in this interview?

Research Participant Consent Form

By signing this document, I am giving my consent to be a participant in this research study investigated by **Mahfuza Talukder Flowra**, WHO-TDR MPH-IR student. I am able to understand that the study is on the “**Barriers of Multi-drugs-resistant Tuberculosis (MDR- TB) detection in National Tuberculosis Program (NTP) in Bangladesh: The Voice of Community**”.

Purpose of the study:

I understand that the research study is in academic purpose and information from the study will be used to obtain information on MDR-TB detection to inform policy makers and to concern all stakeholders to develop strategies that ensure best utilization and maximum coverage of NTP implementation by the community to eliminate TB from Bangladesh.

Research process:

I understand that interview guide/questionnaire will be administered to me by the researcher. I have been informed the data will then be checked for accuracy and completeness and analyzed to produce useful results and recommendations.

Risk and Compensation:

I understand that there is no major risk involved in this study, thus there is no

question of compensation against any kind of harms. So, no monetary compensation will be provided for this study. All my information will be used only for the research purpose of this study. My name will not be disclosed anywhere, and it will be kept confidential.

Benefit:

I have been informed that there are no personal benefits in participating in the study. Participation is only to help research and researcher will not provide any payment for participating in this study.

Confidentiality:

I have been assured that a high degree of confidentiality and privacy of data obtained will be upheld in this study. I have been informed that researcher will not use my name anywhere, and she will use alias when the data will be transcribed. The recorded tape will be kept in a locker after transcription and will be erased after the analysis of the data.

Right:

I have been completely understood that my participation in this study is voluntary and I may choose to end the interview at any time or refuse to answer any question.

Consent:

I hereby agree to participate in this study.

Respondent:		Researcher:	
Name:		Name:	
Signature/Thumb print:		Signature:	

C



UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community
Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc,PhD and Prof. Dr. Ari Probandari, MPH, Ph.D
Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

□□□:

□□□ □□□□□□□□□□□□ **অবগত** □□□ □□□□□□□□ □□□□□□ □□ **এই** □□□□□□□□
□□□□□□□□□□ □□□ □□□ □□□□, □□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□
□□□ □□□□□□□□ □□□ □□□□□□□□□□□ □□□□ □□□ □□□□□□ □□□□□□ □□□□
□□□□□□□ □□□ □□□□□□□□

□□□□□□□□:

□□□ □□□□□□□□□□□□ **অবগত** □□ **এই** □□□□□□□□ □□□□ □□□□ □□□□
□□□□□□□□ □□□□ □□□□ □□□□ □□□□ | □□□□□ □□□□□ □□□□□□□□ □□□□□□□□
□□ □□□□□□□□□□□□ □□□□□ □□□□ □□□ □□□□□ □□□□□□□ □□□□
□□□□□□, □□□□□□□□□□ □□□□□□ **সময়** □□□□□□□□ □□□□□□□□ □□□ □□□□,
□□□□□□□□ □□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□ □□□□ □□□□ □□□□
□□□□□□□□□□□□ **পর** □□ □□□□□ □□□□ □□□□ |

□□□□□□:

□□□ □□□□□□□□□□□□ **অবগত** □□ **এই** □□□□□□□□ □□□□□□□□
□□□□□□□□□□□□, □□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□ **সময়** □□□□
□□□□□□□□□□□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□ □□ □□□□ □□□□ □□□□
□□□□□ □□□□□ |

□□□□□□:

□□□ □□□□□ □□□□ □□□□□□ □□□□□□ □□□□□□

□□□□□□□□□□□□:		□□□□□□:	
□□□:		□□□:	

c

UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community
Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc,PhD and Prof. Dr. Ari Probandari, MPH, Ph.D
Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

□□□□□ ত/□□□□ স:		□□□□□ ত:	
□□□□□:		□□□□□:	

ANNEX II: Questionnaire guidelines

Questionnaire for Multi-Drug-resistant Tuberculosis (MDR-TB)patient

TITLE:Barriers of Multi-drugs-resistant Tuberculosis (MDR- TB) detection in National Tuberculosis Program (NTP) in Bangladesh: the Voice of Community

The following is a questionnaire intended for academic research.

- Any information given in this questionnaire will not be disclosed.
- Participation in this study is voluntary and participants are free to withdraw them at any time.
- For proceeding questions please tick in the right side of appropriate answer.

1. Background Information

No	Question	Option/Answer	Remarks
1.	Gender	Male	
		Female	
2.	Religion	Islam	
		Hinduism	

		Christianity	
		Buddhist	
		Others (specify.....)	
3.	Age in completed years		
4.	Educational Level	Non- formal Education	
		Primary	
		Secondary	
		Higher secondary	
		Graduate	
		Post-graduate	
		Others (specify.....)	
5.	Number of Family Member stay together	< 5	
		> 5	

2. Knowledge about Tuberculosis and MDR-TB Infection

No	Question	Option/Answer	Remarks
1	Do you know about TB/MDR-TB infection?	Yes	
		No	
2	If yes, what are the sources of TB/MDR-TB infection?	Direct contact	
		Droplet	
		Indirect Contact	
		Sexual route	
		Water/Foods	

		Others (specify)	
		Don't know	
3	Source of knowledge about TB/MDR-TB infection	Family	
		Mass Media (TV, Radio, Newspaper)	
		Educational Institutes	
		Health care Centre/ Provider	
		Neighbour/Community	
		Others (specify)	
4	Do you know about symptoms MDR-TB infection?	Yes	
		No	
5	If yes, source of knowledge	Family	
		Mass Media (TV, Radio, Newspaper)	
		Educational Institutes	
		Health care Centre/ Provider	
		Neighbour/Community	
		Others (specify)	
6	What measures do you follow to prevent MDR-TB to others?	Use Mask	
		Use separate utensils	
		Proper ventilation of living space	
		Sleep separately	
		Less time spending among public	
		Hardly use public transport	
		Isolated from children under 5	
		No measure	
		Others (Specify)	

		
7	Do you think MDR-TB a problematic disease?	Yes	
		No	
		Don't know	

3. Knowledge about National Tuberculosis Program (NTP):

No	Question	Option/Answer	Remarks
8	Do you know about NTP?	Yes	
		No	
9	From whom you know about NTP?	Family	
		Educational institutes	
		Mass Media	
		Health Facility/provider	
		Others (specify)	
10	Do you think that NTP is important for timely detection of MDR-TB case?	Yes	
		No	
		Don't know	

4. Perception to participate in NTP:

No	Question	Option/Answer	Remarks
11	Did you go to the nearby health care facility under NTP for diagnosis of your MDR-TB?	Yes	
		No	
12	If No, Why?	No information regarding this	
		It is far away	

		Costly	
		Time consuming	
		There is other alternative way	
		It is not so important	
		Other (specify)	
13	Did you face any difficulties during the detection of of MDR-TB?	Yes	
		No	
14	If yes, what are they?	No information regarding this	
		No sufficient facilities	
		Lengthy procedure	
		Expensive	
		It is not so important	
		Others (specify)	
15	Do all your community members go to HCF to diagnose as a case of MDR-TB?	Yes	
		No	
		Don't know	

5. Barriers and Gaps:

□□□□□ □ □□□□□□□□ □□□□□ □□□□□□□□



No	Question	Option/Answer	Remarks
16	Do MDR-TB diagnosis important?	Yes	
		No	
		Don't know	
17	Do you participate NTP when you are suspected as a MDR-TB case?	Yes	
		No	
18	If no, mention why?	No information	
		Fear of social isolation	
		Other option for diagnosis	
		Distant facility	
		Others (specify).....	
19	Do you think NTP is essential for timely diagnosis MDR-TB?	Yes	
		No	
20	What are some of the barriers to accessing available NTP?	Acceptability of MDR-TB in the community	
		Proximity/Distance travelled	
		Ignorance about the effect of disease	
		Long waiting queues at the program place	
		Cultural resistance	
		No Follow up service	
		Lack of knowledge/Publicity	
		Not enough financial support during lengthy diagnosis procedure	
		Don't know	
Others (specify).....			
21	In your understanding, what is needed to effective NTP	Present is okay	
		Mass Publicity	

C



UNIVERSITAS
GADJAH MADA

implementation for timely detection?	Health education	
	Increase of diagnostic centres	
	Remove social stigma	
	Community Involvement	
	Financial support	
	No comment	
	Other(specify.....)	

□□□□□□ **ঔষধ** □□□□ □□□□□□ □□□□ □□□□ □□□□□□□□□□

□□□□□□□□ □□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□

□□□□□□ **ঔষধ** □□□□ □□□□□□ □□□□ □□□□□□□□□□ □□ □□□□□□

□□□□□□□□□□□□ **জন** □□□□□□

এই □□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□ □□□□□□□□ □□□□

□□□□□□□□ □□□ □□□□ |

- এই □□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□ □□□□
- সাক্ষাতকারে অংশগ্রহণ সম্পূর্ণ ঐচ্ছকি এবং অংশগ্রহণকারী যেকোন সময় তা দয়া থেকে নিজেকে বরিত রাখতে পারবে।
- □□□□□□ □□□□□□ □□□□□□ □ □□□□□□□□□□□□ □□□□ □□□□□□ □□□□ □□□□□□□□

১। □□□□□□□□ □□□□□□

□□□□□□	□□□□□□□□	□□□□□□	□□□□□□□□
১.	□□□□□□	□□□□□□	
		□□□□□□	
২.	□□□□□□	□□□□□□	
		□□□□□□ □□□□□□	
		□□□□□□□□□□□□	
		□□□□□□	



		□□□□□□□□ (□□□□□□ □□□□.....)	
৩.	বয়স (□□□□ □□□□□□)		
৪.	□□□□□□□□ □□□□□□□□	□□□□□□□□□□□□□□ □□□□□□	
		□□□□□□□□	
		□□□□□□□□	
		□□□□ □□□□□□□□□□	
		□□□□□□	
		□□□□□□□□□□□□	
		□□□□□□□□ (□□□□□□ □□□□.....)	
৫.	□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□	< ৫	
		> ৫	

২. □□□□□□□□ □□□□ □□□□□□ **ঔষধ** □□□□ □□□□□□□□ □□□□ □□□□□□□□□□
□□□□□□□□

□□□□ ন	□□□□□□□□	□□□□□□	□□□□□□ □□
১.	□□□□ □□ □□□□□□□□ □□□□ □□□□□□□□ ঔষধ □□□□ □□□□□□□□ □□□□ □□□□□□□□□□ □□□□□□?	□□□□□□	
		□□	
২.	□□□□ □□□□□□□□, □□□□□□ এসব □□□□□□ উৎস □□□□? □□?	□□□□□□□□ □□□□□□□□□□	
		□□□□□□/□□□□□□/□□□□□□	
		□□□□□□□□ □□□□□□□□□□	

C



UNIVERSITAS
GADJAH MADA

		□□□□□□□□□□ □□ □□□□ □□□□ □□□□□□□□	
		□□□□□□□□□□	
		□□□□□□□□□□ □□□□□□□□□□	
		□□□□□ □□□□□ □□□□□ □□□□□ □□□□□	
		□□□□ □□□□□□ □□□□□□ □□□□□□□□□□□□□□ □□□□□ □□□	
		□□□□□□□□□□ (□□□□□□□□ □□□□□.....)	
১৩.	□□□□ □□□□□ এই □□□□ □□□□□□□□□□□□□□ □□□□ □□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□?	□□□□□ □□	
১৪.	□□□□, □□□□□□□□ □□□?	□□□□□□□ □□□ □□□□□ □□ □□□□□ □□□□□ □□□ □□□□□□□□□□ □□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□ □□□□□ □□□	
১৫.	□□□□□□ □□□□□□ একই □□□□□□ □□□□□□□□□□ □□□□□□ এই □□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□?	□□□□□ □□ □□□□□□□□	

C



UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community
Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc,PhD and Prof. Dr. Ari Probandari, MPH, Ph.D
Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

		□□□□□□□□ □□□□□□□□	
		□□□□□□□□□□ □□□□□□ □□□□	
		□□□□□□□□/ □□□□□□□□□□ □□□□	
		□□□□□□ □□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□□ □□□□	
		□□□□□□□□	
		□□□□□□□□□□ (□□□□□□□□ □□□□□.....)	
২১.	□□□□□□ □□□□□□□□□□ , □□□□□□□□ □□□□□□□ □□□□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ আর □□□□□□□ □□□□□□□□□□ □□□□ □□□□?	□□□□□□□ □□□□ □□□□ □□□□ গণ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ জন □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□ □□□□□□□□□□ (□□□□□□□□□□ □□□□□.....)	

ANNEX III: Focus group discussion guide

For community people staying closer to Multi-drug-resistant tuberculosis (MDR-TB) patients



TITLE: Barriers of Multi-drugs-resistant Tuberculosis (MDR- TB) detection in National Tuberculosis Program (NTP) in Bangladesh: the Voice of Community

- Any information given in this questionnaire will not be disclosed.
- Participation in this study is voluntary and participants are free to withdraw them at any time.

Participants	Name	Signature	Age	Sex	Education
P1					
P2					
P3					
P4					
P5					
P6					
P7					
P8					

Before we start, let me introduce myself. My name is Mahfuza Talukder Flowra. I am a medical doctor, currently pursuing my Master in Public Health (Tropical Diseases Research) at Gadjah Mada University, Indonesia.

I am doing some research on Barriers of Multi-drugs-resistant Tuberculosis (MDR- TB) detection in National Tuberculosis Program (NTP) in Bangladesh: the Voice of Community. Results from this study will be expected to find Barriers and gaps existing in the late detection of MDR-TB case of NTP.

To avoid errors and the incomplete information in order to analyze the research, we will record this interview if you are comfortable with it. This recording will not be given to someone else outside the research team. If you grant permission, I would like to record this interview so that I can use it for reference while proceeding with this study.

Questions:

1. What do you know about Tuberculosis and MDR-TB? From where you have heard about MDR-TB infection?
2. What do you know about the bad effects of MDR-TB infections?
3. Do you think MDR-TB is infectious? If yes, what are the way to spread this infection? Please explain.
4. Do you think is it nescissary to take any preventive measures during staying in the common community with the MDR-TB patient? If yes, What kinds of measure you and other members of your family taken? Please tell us in detail.
5. What do you know about National Tuberculosis Program? Do you think that it is important? Tell us how.
6. How do you get information about NTP program. Please tell us.
7. Is there any option rather than NTP for MDR-TB case detection and treatment in your area ?If yes, what are they and what are the advantage or disadvantage of them?
8. How did MDR-TB patient of your community detected as case? Please tell us. Is there any difficulty? If you know, what are they?
9. Is there any difficulties you facing staying with MDR-TB patients in the same community? If yes, what are they?
10. Do any of the health worker/others discuss about MDR-TB patient care in your community? Please explain.
11. Do the care givers of MDR-TB patients are screened for same diseases? Do the children under 5 in the house of MDR-TB patients are gone through Isoniazide Preventive Therapy (IPT) for prevention? Please tell us in details.

C



UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community

Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc, PhD and Prof. Dr. Ari Probandari, MPH, Ph.D

Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

12. What are your suggestions for better implementation of NTP? Please explain.

□□□□□□ □ □ □□□□ □□□□ □□□□□□□□□□□□□□□□

□□□□□□ গুণধ □□□□ □□□□□□□□ □□□□ □□□□□□□□ □□□□□□ □□□□□□ রত

□□□□□□□□□□ □□□□

□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□

□□□□□□ □□□□ □□□□ □□□□ □□□□ □□□□□□□□□□□□ □□ □□□□□□

□□□□□□□□□□□□ □□□□ □□□□□□

- এই □□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□ □□□□
- সাক্ষাতকারে অংশগ্রহণ সম্পূর্ণ ঐচ্ছকি এবং অংশগ্রহণকারী যেকোন সময়ে তা দয়া থেকে নিজেকে বরিত রাখতে পারবে।

□□□□□□□□□□□□	নাম	□□□□□□□□	বয়স	লিঙ্গ	ঠিকানা
P1					
P2					
P3					
P4					
P5					
P6					
P7					
P8					

Questions:

1. Briefly tell us about the journey of your MDR-TB from suspicion to detection?
2. What percentages of community people is suffering from the MDR-TB? What is the usual mode of diagnosis of MDR-TB of your community?? Please explain.
3. How do the other family members and community people treat you as MDR-TB patients? Please tell us in detail.
4. How do the MDR-TB patients of your community diagnose themselves without going under NTP? Are they convenient? Please explain.
5. Do your community keep any record of diagnosed MDR-TB patient ? Please explain.
6. Do your other community member aware about TB/MDR-TB and NTP? Please describe.
7. How do the community people accept NTP for TB/MDR-TB control? What is the importance of the program? Please explain.
8. What are the challenges that need to characterize to maximize the impacts of NTP? Do you think that current system is effective to cover the highest MDR-TB patients in the community?
9. Are there any follow-up sessions after diagnosed as MDR-TB case? Please explain.
10. According to your understanding, what are steps needed for timely detection of MDR-TB CASE for effective NTP implementation? Please explain.

□□□□□ □ □□□□□□□□ □□□□□□□□□ □□□□

□□□□□□□□/□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□□

□□□□

3. Do you think MDR-TB is infectious? If yes, what are the way to spread this infection? Please explain.
4. Do you take any preventive measures during the taking care of the MDR-TB patient of your family? If yes, What kinds of measure you and other members of your family taken? Please tell us in detail.
5. What do you know about National Tuberculosis Program? Do you think that it is important? Tell us how.
6. How do you get information about NTP program. Please tell us.
7. Is there any option rather than NTP for MDR-TB case detection in your area ?If yes, what are they and what are the advantage or disadvantage of them?
8. How did MDR-TB patient of your family detected as case? Please tell us. Is there any difficulty? If yes, what are they?
9. Do you face any difficulties during taking care of MDR-TB patient in house or community? If yes, what are they?
10. Do any of your health worker/others discuss about MDR-TB patient care in your house/ community? Please explain.
11. What are your suggestions for better implementation of NTP? Please explain.

□□) □□□□□ □□□□□□ □□□□□ **ঔষধ** □□□□ □□□□□□ □□□□□

□□□□□□□□□□□□ □□□□□

□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□

□□□□□□ **ঔষধ** □□□□ □□□□□□□ □□□□ □□□□□□□□□□ □□□□ □□□□□

□□□□□□□□□□□□ **জন** □□□□□

• এই □□□□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□□ □□□□ □□□□□□□□□□

• সাক্ষাতকারে অংশগ্রহণ সম্পূর্ণ ঐচ্ছকি এবং অংশগ্রহণকারী যেকোন সময়ে তা দয়া থেকে নিজেকে বরিত রাখতে পারবে।

□□□□□□□□□□□□ □□□□□□□□□□

□□□		বয়স		□□□□	
□□□□□□					



C

UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community

Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc, PhD and Prof. Dr. Ari Probandari, MPH, Ph.D
Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

১১) □□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□ আর □□□□□□□□

□□□□□□□□□□ □□□□ □□□ □□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□

□□□□□□

C. For Community Health Workers

TITLE: Barriers of Multi-drugs-resistant Tuberculosis (MDR- TB) detection in National Tuberculosis Program (NTP) in Bangladesh: the Voice of Community

- Any information given in this questionnaire will not be disclosed.
- Participation in this study is voluntary and participants are free to withdraw them at any time.

Background Information:

Name		Age		Sex	
Address					

Questions:

1. What TB diseases related services available to the community at this facility? What has this organization done to provide information to the community in this area regarding TB diseases?
2. Does this organization work with the community improve measures aimed to control or prevent TB and MDR-TB? What are some of the measures taken to improve communities to prevent these diseases? What community-based outreach activities this organization offer to increase awareness against NTP?
3. How do community, family and close associate relate to people with the disease? (the nature of stigmatization)
4. How this community implement MDR-TB diagnosis under NTP? In your opinion did everyone diagnosed as MDR-TB in the community go for the treatment?
5. Do this community have any routine follow-up after diagnosed as a MDR-TB case?

C



UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community

Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc,PhD and Prof. Dr. Ari Probandari, MPH, Ph.D
Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

6. How this community diagnose themselves as a case of TB or MDR-TB case? Is there any difficulty regarding this? Please explain.
7. Do the other family members of MDR-TB patient goes under compulsory screening test for MDR-TB?
8. Do you experience any discrimination between MDR-TB patient and other family member having that diseases? Please explain?
9. Do you experience any social discrimination to the MDR-TB patients from the community people due to their diseases? Please tell us.
10. In your understanding, what are the reasons why this area still facing the challenge of NTP implementation?
11. In your opinion, how can be NTP services in this community improved to meet community needs?

□□) □□□□□□ □□□□□□□□□□□□□□□□ □□□□

□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□

□□□□□□ **ঔষধ** □□□□ □□□□□□□□ □□□□ □□□□□□□□□□□□ □□□ □□□□□□

□□□□□□□□□□□□ **জন** □□□□□□

- এই □□□□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□□ □□□□ □□□□ □□□□
- সাক্ষাতকারে অংশগ্রহণ সম্পূর্ণ ঐচ্ছকি এবং অংশগ্রহণকারী যেকোন সময়ে তা দয়া থেকে নিজেকে বরিত রাখতে পারবে।

□□□□□□□□□□□□ □□□□□□□□□□

□□□		বয়স		□□□□	
□□□□□□					

□□□□□□□□□□□□:



1.1 What is your comments about the overall National Tuberculosis program in your areas?

Question 2: Current view on MDR-TB

2.1 What is your comments about MDR-TB care in general?

2.2 What do you say about the current detection coverage of MDR-TB cases in your area?

Question 3: MDR-TB policy and implementation structure in NTP

3.1 Is there any standard policies, strategies, and SOPs in place that generally supports the current MDR-TB diagnosis in Bangladesh?

3.2 If yes, please explain the current strategies to combat MDR-TB challenge implementation under NTP?

3.3 If yes, how is this structured or supported by the government: administratively, technically, and financially?

3.4 How committed are the related stakeholders? Do they deliver this service wholeheartedly?

Question 4: Monitoring and performance indicators

4.1 Is there any government performance indicator of NTP implementation that measures the implementation outcomes?

4.2 What is the target for lowering TB prevalence per year? Please specify.

4.3 According to the previous reports, has this target been reached this year or previously?

4.4 If yes, what are some of the things that made it achievable?

4.5 If no, what are some of the reasons that it did not reach the target? (Move to 4.6)

4.6 In 4.5 above, has there been anywhere this has been improved sometimes?

Question 5: Challenges, gaps, and issues

C



UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community

Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc,PhD and Prof. Dr. Ari Probandari, MPH, Ph.D

Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

5.1 Do you think there is any gap or challenges within the MDR-TB diagnosis implementation?

5.2 If yes, what are some of the gaps or challenges that you can identify for MDR-TB detection implementation?

Question 6: Improvements and way forward

6.1 What do you think, or in what ways do you think we can mend this gap to achieve national target?

6.2 Do you have any idea in general on what are some of the things that government should need do to improve coverage of timely detection of MDR-TB?

6.3 Is there anything that you highly recommend for the ministry to minimise the challenges in your areas?

□□□□□□ □□ □□□□ □□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□

□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□

□□□□□□□□□□ □□□□

□□□□□□□□ □□□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□

□□□□□□ **ঔষধ** □□□□ □□□□□□□□ □□□□ □□□□□□□□□□ □□□ □□□□□

□□□□□□□□□□□□ **জন** □□□□□

- এই □□□□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□□ □□□□ □□□□ □□□□
- সাক্ষাতকারে অংশগ্রহণ সম্পূর্ণ ঐচ্ছকি এবং অংশগ্রহণকারী যেকোন সময়ে তা দয়া থেকে নিজেকে বরিত রাখতে পারবে।

নপেথ্য তথ্যঃ

নাম		বয়স		লিঙ্গ	
-----	--	------	--	-------	--

C



UNIVERSITAS
GADJAH MADA

Barriers of Multi-drugs resistant Tuberculosis (MDR- TB) detection in National Tuberculosis control Program (NTP) in Bangladesh: The Voice of Community
Flowra, Mahfuza Talukder, Dr. Yodi Mahendradhata, MSc, PhD and Prof. Dr. Ari Probandari, MPH, Ph.D
Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

প্রশ্ন নং ৪:

৪.১ □□□□ □□□□□□ □□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□
□□□ □□□□□□ □□□□□□ □□□ □□?

৪.২ □□□□ □□□□ □□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□□□□
□□□? □□□ □□□ □□□□□□□□□□□□ □□□□ |

৪.৩ □□□□ □□□□□□ □□□□□□ এ □□□□□ □□□□□□□□□□ □□ □□□□□□
□□□□□?

৪.৪ □□□ □□□ □□□□, □□□□□□ □□□ □□□□□ □□□□□ □□□□□?

৪.৫ □□□ □□ □□□ □□□□ □□ □□ □□□□□ □□□ □□□□□ □□□ □□□ □□□ □□□
□□□□?(৪.৬ এ □□□□)

৪.৬ □□□□□□ □□□□ □□□□□□ □□□□□?

□□□□□ ৫:

৫.১ □□□□□ □□□ □□□□□□ □□□□ □□□□ □□□□□□□□□□□□ □□□□
□□□□ □□□□□□□□ □□□ □□??

৫.২ □□□ □□□□ □□□□, □□□□□□ □□ □□?

□□□□□ ৬:

৬.১ □□□□□ □□□ □□□□□□ □□□□□□□□□□□□ □□□□□ □□□□ □□□□
□□□□ এই □□□□□□□ □□□□ □□□□□□□ □□□ □□□□□?

৬.২ □□□□ □□ □□□□ □□□□□□□□ □□□□□ □□□□ □□□□□ □□□□□
□□□□□□□□□□ □□□□ □□□ □□□□□□ □□□□ □□□□□□ □□□□ □□□□□□□□□□
সনাক্তকরণ সম্ভব?

৬.৩ □□□□ □□ □□□□□ □□□□□□ □□□□□□□ □□□□ □□□□□□□□ □□□□□□□□
□□□□ □□□□ □□□□□□□□ □□□□ □□□?

B. For Program Manager from NGO(.....)

TITLE:Barriers of Multi-drugs-resistant Tuberculosis (MDR- TB) detection in National Tuberculosis Program (NTP) in Bangladesh: the Voice of Community

- Any information given in this questionnaire will not be disclosed.
- Participation in this study is voluntary and participants are free to withdraw them at any time.

Background Information:

Name		Age		Sex	
Address					

Questions:

Questions 1: System Overview

1.1 What is your comments about the overall National Tuberculosis program in your areas?

Question 2: Current view on MDR-TB

2.1 What is your comments about MDR-TB care in general?

2.2 What do you say about the current detection coverage of MDR-TB cases in your area?

Question 3: MDR-TB policy and implementation structure

3.1 Is there any standard policies, strategies, and SOPs in place that generally supports the current MDR-TB diagnosis in Bangladesh?



- 3.2 If yes, please explain the current strategies to combat MDR-TB challenge implementation under NTP?
- 3.3 If yes, how is this structured or supported by the government: administratively, technically, and financially?
- 3.4 How committed are the related stakeholders? Do they deliver this service wholeheartedly?

Question 4: Monitoring and performance indicators

- 4.1 Is there any government performance indicator of MDR-TB care implementation that measures the implementation outcomes?
- 4.2 What is the target for coverage to achieve each year? Please specify.
- 4.3 According to the previous reports, has this target been reached this year or previously?
- 4.4 If yes, what are some of the things that made it achievable?
- 4.5 If no, what are some of the reasons that it did not reach the target? (Move to 4.6)
- 4.6 In 4.5 above, has there been anywhere this has been improved sometimes?

Question 5: Challenges, gaps, and issues

- 5.1 Do you think there is any gap or challenges within the MDR-TB diagnosis implementation?
- 5.2 If yes, what are some of the gaps or challenges that you can identify for MDR-TB detection implementation ?

Question 6: Improvements and way forward

- 6.1 What do you think, or in what ways do you think we can mend this gap to achieve national target?
- 6.2 Do you have any idea in general on what are some of the things that government should need do to improve coverage of timely detection of MDR-TB?
- 6.3 Is there anything that you highly recommend for the ministry to minimise the challenges in your areas?

